Slide 1: Alcon, Inc. Annual General Meeting
Exhibit 99.2 Alcon, Inc. Annual General Meeting April 7, 2011 1
Slide 2: Attractive Growth Opportunity
Attractive Growth Opportunity Strategically focused on important medical specialty Eye care is a fast-growing health care specialty sector Vision management is a health care priority Long-term growth opportunity Aging global population Significant unmet clinical needs in ophthalmology Expanding medi
Slide 3: Alcon Will Be Second Largest Growth Platform
Alcon Will Be Second Largest Growth Platform 2010 pro forma Novartis Group net sales: USD 55.4 billion1 1 2 3 4 5 Alcon1 Sandoz Consumer Vaccines & Pharma y Care2) ((Eye ((Generics)) Health Diagnostics g USD 30.2 USD 9.4 USD 8.5 USD 4.4 USD 2.9 billion1,2 billion1 billion billion1 billion Most NME
Slide 4: New Alcon Eye Care Division
New Alcon Eye Care Division Select Novartis Ophtha Alcon CIBA VISION Pharma Assets Strategic benefits of combination Potential to expand the commercial capability around contact lenses and care products on a global basis Creates market leading eye care specialty unit Growth platform p 4
Slide 5: Benefits to Alcon
Benefits to Alcon Ownership and direction from a strategic healthcare leader Potential to expand the commercial capability around contact lenses and care products on a global basis Access to broad-based pharmaceutical research capability Potential to leverage Alcon’s leadership position through: Eme
Slide 6: Merger Consideration
Merger Consideration $54.67 Novartis share value calculated based on US dollar volume- weighted average Novartis price for the 10 trading days beginning on March 24 and ending on April 6 Share exchange ratio of 2.9228 shares based on 2.8 base ratio plus dividend adjustment factor Cash contingent val
Slide 7: Alcon, Inc. Annual General Meeting
Alcon, Inc. Annual General Meeting April 7, 2011 7
Slide 8: Delivered Solid 2010 Performance
Delivered Solid 2010 Performance Sales rose 10.5% to $7.2 billion Constant currency growth of 9.2% Strong performance driven by commercial execution and global market share gains Operating p g profit p increased 9.5% to $2.5 $ billion Diligent management of expenses Increased investment in research
Slide 9: Balanced Global Contributions
Balanced Global Contributions 2010 Sales by Geography $1,411 Reported: +21.3% +21 3% Constant Currency: +17.1% $3,177 Reported: +9.0% Total T t l International I t ti l $4,002 Reported: +11.6% Constant Currency +9.3% $2,591 Reported: +7.0% Constant Currency: +5.6% (dollars in millions) Growth rates
Slide 10: New Products Driving Glaucoma Growth
New Products Driving Glaucoma Growth Gl b l Gl Global Glaucoma M k t Sh Market Share G th Growth DuoTrav® and AZARGA® combined delivered 60.8% sales growth in 2010 3.2% Source: IMS (top 32 countries) ® ® Growth rate as compared to same period in prior year. 10
Slide 11: AT-IOLs Delivering Consistent Sales Growth
AT-IOLs Delivering Consistent Sales Growth Advanced Technology IOL Global Sales 2010 +21.4% ars in millions)) (dolla Growth rate as compared to same period in prior year. 11
Slide 12: 2010 Key Late Stage R&D Pipeline Activity
2010 Key Late Stage R&D Pipeline Activity 2010 SUBMISSIONS 2010 APPROVALS ALLEGRETTO™ EX-500 Ex-PRESS® ophthalmic TRAVATAN® Alternative Patanase® new indication refractive laser (EU) glaucoma device (Japan) Preservative System (EU) (US) TRAVATAN® Alternative AcrySof® IQ Toric expanded AcrySof® IQ Re
Slide 13: Business Development Delivering Growth
Business Development Delivering Growth Optonol Acquisition Broadens Alcon’s extensive glaucoma product offering Sales of EX-PRESS® glaucoma filtration device building DUREZOL® Acquisition q Adds potent steroid to Alcon’s portfolio Generating near-term sales momentum Market share gains exceeding plan
Slide 14: Exciting New Cataract Technology
Exciting New Cataract Technology LenSx Acquisition LenSx femtosecond laser improves key steps in cataract surgery Uses technology to automate previously manual procedures Micron-level laser precision and predictability Provides new growth driver to Alcon’s leading cataract portfolio Complementary pr
Slide 15: Strong Top-line Sales Growth
Strong Top-line Sales Growth Full Year Global Sales (dollars in millions) +10.5% 10.5% Reported +9.2% Constant Currency $7 179 $7,179 $6 499 $6,499 Growth rates as compared to same period in prior year Constant currency growth is a non-GAAP measure presented to give investors a better comparison of
Slide 16: Balanced Global Growth
Balanced Global Growth U.S. / International Sales Growth 2010 Sales Growth Constant Reported Currency ons) dollars in millio 44.3% +9.0% +9.0% 44.6% 44.8% 47.7% 50.3% (d 37.3% 36.0% +7.0% +5.6% 37.1% 36.8% 35.1% 14.6 % 1 % 15.5% 18 3% 18.3% 17 9% 17.9% 19 7% 19.7% +21 3% +21.3% +17 1% +17.1% Growth
Slide 17: Diversification Across Therapeutic Areas
Diversification Across Therapeutic Areas Full Year Global Sales by Product Line +14.5% Reported +7.4% Reported +8.2% Reported +13.7% 13 7% C Constant t tC Currency 6 0% C +6.0% Constant t tC Currency +6.3% 6 3% C Constant t tC Currency ons) ollars in millio (do Growth rates as compared to same perio
Slide 18: Operating Income
Operating Income Full Year Reported (dollars in millions) +9 5% +9.5% $2,475 $2,261 % of 34.8% 34.5% Sales Growth rate as compared to same period in prior year 18
Slide 19: Net Earnings and Diluted EPS
Net Earnings and Diluted EPS Full Year Reported (dollars in millions, except EPS) +10 1% +10.1% EPS $7.27 $7 27 $2,210 EPS $6.66 $2,007 % of 30.9% 30.8% Sales Growth rate as compared to same period in prior year 19
Slide 20: Non-GAAP Reconciliations
Non-GAAP Reconciliations Foreign Constant Currency Currency 2010 Sales Change Change Change Total global 10.5 % 1.3 % 9.2 % United States 9.0 - 9.0 International 11.6 2.3 9.3 Developed international 7.0 1.4 5.6 Emerging markets 21.3 4.2 17.1 Pharmaceutical 14.5 0.8 13.7 Surgical 7.4 1.4 6.0 Consumer
Slide 21: Alcon, Inc. Annual General Meeting
Alcon, Inc. Annual General Meeting April 7, 2011 21